The study is a multi-center, open-label, and single-arm trial to evaluate the safety and efficacy in destroying liver tumors and will build upon the company’s first-in-man THERESA Study recently conducted in Barcelona, Spain.

Prone positioning for a lateral approach presents an exciting opportunity for streamlining surgical access to the lumbar spine and facilitating a more efficient surgical solution with potential clinical and economic advantages for certain patients.

NEUWAVE Microwave Ablation System is a minimally invasive technology that uses heat transmitted through image-guided needle-like probes to destroy targeted soft tissue lesions in the liver, kidneys and lungs.

The final two-year data from the STAR-I trial and the six-month follow-up data from the STAR-II European trial, which are comprised in the pooled analysis, will both be presented at the upcoming European Society of Cataract and Refractive Surgery (ESCRS) meeting on October 2-4. The six-month primary endpoint results from the STAR-II trial of MINIject have recently been published in the peer-reviewed Journal of Glaucoma, the official publication of the World Glaucoma Association.

The Trans-Apical TMVR procedure was performed as part of an on-going European clinical trial on August 19, 2020 at Santaros Klinikos University Hospital in Vilnius, Lithuania with the Heart Team of Kęstutis Ručinskas, MD, Audrius Aidietis MD, Vilius Janušauskas, MD, and Valdas Bilkis, MD supported by Paolo Denti, MD and Stefano Stella, MD.